V600E mutations are frequent in melanomas originating from intermittently sunexposed skin and also in common acquired melanocytic nevi, suggesting that BRAF mutation is an early event in melanocytic neoplasia. All neoplastic melanocytes within such a nevus would be expected to carry the BRAF mutation, and thus we evaluated the frequency of cells with BRAF V600E mutations within acquired nevi by droplet digital polymerase chain reaction. In BRAF-mutant nevi the number of BRAF mutant alleles equaled the number of wild-type (WT) alleles in the neoplastic cell population, consistent with a fully clonal heterozygous BRAF mutation. The allelic ratio of BRAF V600E to BRAF WT in the eight VE1-positive nevi, adjusted for degree of stromal contamination, ranged from 0.84 to 1.12 with an average ratio of 1.01. This was confirmed by immunohistochemistry with an antibody specific for BRAF V600E , which uniformly labeled the neoplastic cells without any evidence of heterogeneity. We found BRAF V600E mutations in the melanocytic nevi to be fully clonal, strongly suggesting that BRAF-activating mutations typically are early initiating events in melanocytic neoplasia.
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V600E mutations are frequent in melanomas originating from intermittently sunexposed skin and also in common acquired melanocytic nevi, suggesting that BRAF mutation is an early event in melanocytic neoplasia. All neoplastic melanocytes within such a nevus would be expected to carry the BRAF mutation, and thus we evaluated the frequency of cells with BRAF V600E mutations within acquired nevi by droplet digital polymerase chain reaction. In BRAF-mutant nevi the number of BRAF mutant alleles equaled the number of wild-type (WT) alleles in the neoplastic cell population, consistent with a fully clonal heterozygous BRAF mutation. The allelic ratio of BRAF V600E to BRAF WT in the eight VE1-positive nevi, adjusted for degree of stromal contamination, ranged from 0.84 to 1.12 with an average ratio of 1.01. This was confirmed by immunohistochemistry with an antibody specific for BRAF V600E , which uniformly labeled the neoplastic cells without any evidence of heterogeneity. We found BRAF V600E mutations in the melanocytic nevi to be fully clonal, strongly suggesting that BRAF-activating mutations typically are early initiating events in melanocytic neoplasia. Activating BRAF mutations in melanocytic neoplasia were originally discovered in melanoma. Subsequent studies identified similar mutations in the majority of melanocytic nevi (82%), suggesting that BRAF mutations occur early during melanocytic transformation, possibly as an initiating event (1) . The fact that the majority of nevi arise early in life, primarily during the first two decades, and also in multiplicity, with an average 40-yearold having 40 nevi, also suggests that the number of genetic alterations required for their formation must be small (2). This notion is further supported by animal models in which mutant BRAF expression in melanocytes leads to benign melanocytic tumors and only in the context of additional genetic alterations progression to melanoma is observed (3, 4) . Based on these considerations, it appears likely that BRAF mutations represent an initiating event, which, in susceptible individuals, is sufficient to generate nevi. -specific antibody, VE1 (7), to further evaluate the distribution of BRAF V600E mutations within the neoplastic melanocytes of nevi (Supplementary Methods, available online). We selected formalin-fixed, paraffin-embedded tissues from 10 acquired melanocytic nevi (compound and intradermal) from the archives of the Dermatopathology Section of the University of California, San Francisco, under approval of the institutional review board. All nevi underwent immunohistochemistry with the VE1 mouse monoclonal antibody (7). Eight of 10 cases demonstrated uniform immunoreactivity for VE1 of the entire neoplastic population of melanocytes, sparing stromal cells (Figure 1 ), whereas two nevi were entirely negative (Supplementary Figure 1, available online) .
For all nevi, DNA was extracted from tissue sections that were manually microdissected to remove the epidermis and hair follicles. BRAF V600E and BRAF wild-type (WT) alleles were quantitated for each sample by ddPCR. In ddPCR, the DNA sample is equally partitioned into thousands of aqueous droplets suspended in a water in oil emulsion. The emulsion is subjected to thermal cycling, in which the DNA within each droplet undergoes amplification, in the presence of two TaqMan probes for the WT and mutant allele, respectively. At the end, droplets in which sequence complementary to the TaqMan probe was amplified can be detected by specific fluorescence. The number of droplets containing a specific allele is used to quantitate the concentration of that allele within the sample. This method allows the enumeration of alleles in a large number of starting cells, and is not subject to allele dropout (8) , which can skew results when DNA is isolated and amplified from a small number of starting cells. The eight nevi that were positive by VE1 immunohistochemistry showed BRAF V600E to BRAF WT allelic ratios between 0.61 and 0.79 (Figure 2A ). For the two cases negative by VE1 immunohistochemistry, the BRAF V600E to BRAF WT allelic ratios were less than 0.001, similar to normal control DNA (Figure 2 , B and C; Supplementary  Figure 2 , available online).
BRIef CoMMuNICatIoN
To correct for dilution of the mutant allele frequency by normal DNA contributed by stromal cells, we estimated stromal contamination of the microdissected tissues by two-color fluorescence microscopy with antibodies against Sox-10 or a cocktail of antibodies against HMB-45, MART-1, and tyrosinase (pan-melanoma), both of which highlight melanocytes, and 4',6-diamidino-2-phenylindole counterstain to identify nuclei. At least 300 cells from representative regions corresponding to the microdissected areas were evaluated for Sox-10 or pan-melanoma positivity ( Figure 2D ). Stromal contamination was estimated as the proportion of cells that reacted with neither Sox-10 nor pan-melanoma antibodies and the measured number of WT BRAF alleles was adjusted accordingly. The corrected allelic ratio of BRAF
V600E
to BRAF WT in the eight VE1 positive nevi ranged from 0.84 to 1.12 with an average ratio of 1.01 ( Figure 2E) . A ratio of 1.0 would be the expected finding, if all neoplastic melanocytes carried one mutant and one WT BRAF allele. Our results are at variance with the genotyping performed by Lin et al. (5) where PCR was performed on DNA extracted from single cells. As not all template molecules in the starting material can be successfully amplified, this approach can miscalculate allelic ratios, when, for example, the mutant allele "drops out" (8) . This problem is accentuated in the presence of normal cells, where the likelihood of dropout of the mutant is increased over the WT allele. The methods used for nevus cell isolation in Lin et al. (5) are not 100% specific, and thus stromal contamination could be a potential source of error. In contrast, our methods sample a large number of nevus cells, and we subsequently correct for stromal contamination.
In our study, the data from both methods-the expression of BRAF V600E protein as determined by immunohistochemistry and the allelic ratios determined by ddPCRstrongly suggest that the BRAF V600E mutation is present in the majority, if not all melanocytes in BRAF V600E nevi. Although our sample size was small, the consistency of the results obtained supports the model that BRAF mutation is an early initiating event that drives clonal expansion.
